KKR launched Allyntra, a precision-engineered solutions platform, to serve the medical technology and high-precision industrial markets by building on its investment in Precipart. Meanwhile, KKR is reportedly exploring a potential takeover of Qiagen alongside other private equity firms, causing Qiagen's shares to surge. Additionally, Spero Therapeutics shares declined following the announcement of a $105 million funding agreement with KKR.
